



HAL
open science

Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein

Claire Montpellier, Czeslaw Wychowski, Ibrahim M Sayed, Jean-Christophe Meunier, Jean-Michel Saliou, Maliki Ankavay, Anne Bull, André Pillez, Florence Abravanel, François Helle, et al.

► **To cite this version:**

Claire Montpellier, Czeslaw Wychowski, Ibrahim M Sayed, Jean-Christophe Meunier, Jean-Michel Saliou, et al.. Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. *Gastroenterology*, 2018, 154 (1), pp.211-223.e8. 10.1053/j.gastro.2017.09.020 . hal-02117643

HAL Id: hal-02117643

<https://hal.science/hal-02117643>

Submitted on 2 May 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Title:**2 **Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid**
1
3 **Protein**
34
5
6 **Short title:**
78 New insights into HEV lifecycle
910
11
12 **Authors:**13
14 Claire Montpellier^{a,#}, Czeslaw Wychowski^{a,#}, Ibrahim M. Sayed^{b,c}, Jean-Christophe Meunier^d, Jean-
15 Michel Saliou^a, Maliki Ankavay^a, Anne Bull^d, André Pillez^a, Florence Abravanel^e, François Helle^f,
16 Etienne Brochot^f, Hervé Drobecq^g, Rayan Farhat^a, Cécile-Marie Aliouat-Denis^a, Juliano G. Haddad^a,
17 Jacques Izopet^e, Philip Meuleman^b, Anne Goffard^a, Jean Dubuisson^a, Laurence Cocquerel^a
18
1920
21
22
23
24 ^a University of Lille, CNRS, INSERM, CHU Lille, Pasteur Institute of Lille, U1019-UMR8204-CIIL-
25 Center for Infection and Immunity of Lille, F-59000 Lille, France26
27 ^b Laboratory of Liver Infectious Diseases, Department of Clinical Chemistry, Microbiology and
28 Immunology, Ghent University, Ghent, Belgium.29
30 ^c Microbiology and Immunology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.31
32 ^d Inserm-U966, University F. Rabelais, F-37032 Tours, France.33
34
35 ^e CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E,
36 F-31300, France.37
38 ^f EA4294, Laboratoire de Virologie, Centre Universitaire de Recherche en Santé, Centre Hospitalier
39 Universitaire et Université de Picardie Jules Verne, Amiens, France
4041
42 ^g Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161-M3T-Mechanisms of Tumorigenesis and
43 Target Therapies, Lille, France.44
45
46 [#] CM and CW contributed equally to this work
4748
49 **Grant Supports:**50 This work was supported by the French “Agence Nationale de la Recherche sur le Sida et les hépatites
51 virales” (ANRS) and the University of Lille. M. A. was supported by a fellowship from the ANRS.52 P.M was supported by grants from the Research Foundation Flanders (FWO Vlaanderen), Ghent
53 University (BOF GOA and IRO), and the Belgian State (BELSPO IAP HEPRO-2). I.M.S was
54 supported with PhD fellowships from the Egyptian Government and Ghent University. J.G.H was
55 supported by a fellowship from the Lebanese Association for Development.
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abbreviations:

aa, amino acid; Ag, antigen; BFA, brefeldin A; DMEM, Dulbecco's modified Eagle's medium; DT, sodium deoxycholate and trypsin treatment; EndoH, endoglycosidase H; ER, endoplasmic reticulum; FCS, fetal calf serum; ffu, focus forming unit; GLuc, *Gaussia* luciferase; GNA, *Galanthus nivalis* agglutinin; gt, genotype; HCV, hepatitis C virus; HEV, hepatitis E virus; HEVcc, cell culture-produced HEV particles; HEVser, HEV particles from patient serum; IC, immunocapture; MAb, monoclonal antibody; nanoLC-MS/MS, nano scale Liquid Chromatography coupled to tandem Mass Spectrometry; Neura, neuraminidase; O-Gly, O-glycosidase; ORFs, open reading frames; PBS, phosphate buffered saline; p.e., post-electroporation; PHH, primary human hepatocytes; PNGaseF, peptide-N-glycosidase F; RLU, relative luciferase unit; RT-qPCR, real-time-quantitative polymerase chain reaction; SD, standard deviation; SFV, Sofosbuvir; SP, signal peptide; TEM, transmission electron microscopy; WB, western blotting.

Correspondence:

Dr Laurence Cocquerel, Molecular & Cellular Virology, CIIL, CNRS-UMR8204 & Inserm-U1019, Institut Pasteur de Lille, Bâtiment IBL, 1 rue du Pr. Calmette, CS50447, 59019 Lille cedex, France.
E-mail: laurence.cocquerel@ibl.cnrs.fr

Dr Czeslaw Wychowski, Molecular & Cellular Virology, CIIL, CNRS-UMR8204 & Inserm-U1019, Institut Pasteur de Lille, Bâtiment IBL, 1 rue du Pr. Calmette, CS50447, 59019 Lille cedex, France.
E-mail: czeslaw.wychowski@ibl.cnrs.fr

Disclosures:

All authors disclose no conflicts.

Author contributions:

Conceived and designed the experiments: CM, CW, IMS, JCM, JMS, MA, AB, AP, PM, JD, LC.

Performed the experiments: CM, CW, IMS, JCM, JMS, MA, AB, AP, HD, JGH, LC.

Analyzed the data: CM, CW, IMS, JCM, JMS, PM, JD, LC.

Contributed reagents/materials/analysis tools: FA, FH, EB, RF, CMAD, JI, PM, AG.

Wrote the paper: LC.

Word count:

Main text (Abstracts -Introduction-M&M-Results-Discussion-References): 7007

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Background & Aims: Hepatitis E virus (HEV) infection is a major cause of acute hepatitis worldwide. Approximately 2 billion people live in areas endemic for HEV and are at risk of infection. The HEV genome encodes 3 proteins, including the ORF2 capsid protein. Detailed analyses of the HEV lifecycle has been hampered by the lack of an efficient viral culture system.

Methods: We performed studies with gt3 HEV cell culture-produced particles (HEVcc) and patient blood and stool samples. Samples were fractionated on iodixanol gradients and cushions. Infectivity assays were performed in vitro and in human liver chimeric mice. Proteins were analyzed by biochemical and proteomic approaches. Infectious particles were analyzed by transmission electron microscopy. HEV antigen levels were measured with the Wantai ELISA.

Results: We developed an efficient cell culture system and isolated HEV particles that were infectious in vitro and in vivo. Using transmission electron microscopy, we defined the ultrastructure of HEVcc and particles from patient sera and stool samples. We also identified the precise sequence of the infectious particle-associated ORF2 capsid protein. In cultured cells and in samples from patients, HEV produced 3 forms of the ORF2 capsid protein: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein associated with infectious particles, whereas the ORF2g and ORF2c proteins were massively secreted glycoproteins not associated with infectious particles. ORF2g and ORF2c were the most abundant antigens detected in sera from patients.

Conclusions: We developed a cell culture system and characterized HEV particles; we identified 3 ORF2 capsid proteins (ORF2i, ORF2g, and ORF2c). These findings will advance our understanding of the HEV lifecycle and improve diagnosis.

KEY WORDS: Hepatitis E, PLC/PRF/5 cells, infectious particles, ORF2 products

1 Introduction

2 Hepatitis E virus (HEV) is the leading cause of enterically transmitted viral hepatitis globally,
3 and is responsible for 20 million infections and 70,000 deaths every year ¹. Though HEV infection is
4 usually self-resolving, severe forms or chronic infections have been described, mainly in
5 immunocompromised patients. A high rate of mortality has also been reported among pregnant
6 women. HEV infection has also been associated with extrahepatic disorders, including renal and
7 neurological disorders ². Four genotypes (gt) are pathogenic in humans. Gt1 and gt2 exclusively infect
8 humans, while gt3 and gt4 are zoonotic and mainly infect animals that may transmit the virus to
9 humans. Recently, gt3 infections have been emerging in the Western world, likely due to contaminated
10 blood transfusions and the consumption of contaminated food ¹. The diagnosis of hepatitis E is based
11 on the detection of anti-HEV antibodies and/or viral RNA in patient serum ³. Recently, a new assay
12 based on detecting the HEV capsid protein antigen was developed (Wantai Biologicals), especially for
13 laboratories with no molecular diagnosis facilities.

14 HEV is a quasi-enveloped, positive-sense RNA virus expressing three open reading frames
15 (ORFs): ORF1, ORF2 and ORF3 ¹. ORF1 encodes the ORF1 non-structural polyprotein, which
16 contains several functional domains essential for viral replication. ORF2 encodes the ORF2 viral
17 capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing
18 antibodies. ORF3 encodes a small multifunctional phosphoprotein involved in virion morphogenesis
19 and egress. Although HEV is a non-enveloped virus in bile and feces, patient serum and cell culture-
20 produced particles have been described to be associated with cellular lipids, as for Hepatitis A virus ⁴,
21 and display the ORF3 protein at their surface ⁵.

22 The growth of HEV in cell culture has been proven to be very difficult ⁵. However, several
23 HEV strains have been adapted to cell culture, including the gt3 Kernow C-1 strain, which contains an
24 insertion of a 58-aa human S17 ribosomal protein ⁶. Although these systems have led to increased
25 understanding of the HEV lifecycle, they still produce low infectious titers, limiting direct biochemical
26 analysis of viral proteins and infectious material. Notably, the exact sequence of infectious particle-
27 associated ORF2 protein is unknown. In addition, the ultrastructure of particles has never been
28 robustly studied by immune electron microscopy.

29 In our study, we describe an HEV cell culture system that leads to early and massive expression
30 of viral proteins and infectious particles, permitting their direct biochemical analysis. For the first time,
31 we define the ultrastructure of HEV particles by electron microscopy and identify the precise sequence
32 of the infectious particle-associated ORF2 capsid protein. We demonstrate that in infected cell culture
33 and patients, at least three forms of the ORF2 capsid protein are produced. The two major ORF2
34 proteins are not associated with infectious particles, despite being the major antigens present in HEV-
35 infected patient sera.

1 **Materials and Methods**

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

Chemicals and cell cultures. PLC/PRF/5 (CRL-8024), PLC1, PLC3 and A549 (CCL-185) cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% inactivated fetal calf serum (DMEM/FCS) at 37°C. Transfected cells were maintained at 32°C in a medium containing DMEM/M199 (1v:1v), 1mg/ml of lipid-rich albumin (Albumax I™) and 40nM Na₂SeO₃.

Plasmids and transfection. Plasmids expressing the cell culture adapted gt3 Kernow C-1 strain (HEV-p6, GenBank accession number JQ679013) or the replicon expressing the *Gaussia* luciferase gene (HEV-p6GLuc) were provided by S.U Emerson ⁶. The replication-deficient replicon HEV-p6GLucGAD was generated by mutating the GDD motif into the RNA-dependent RNA polymerase gene ⁷. Capped RNA transcripts were generated with the mMACHINE mMESSAGE kit (Ambion). Capped RNAs were delivered to cells by electroporation using a Gene Pulser Xcell™ apparatus (Bio-Rad).

25 **Kinetics experiments and virus production.**

PLC1 and PLC3 cells were electroporated with capped HEV-p6 RNA (20μg/4x10⁶ cells). For kinetics experiments, every two days, supernatants were harvested and cells were lysed in buffer containing 50mM TrisHCl (pH 7.5), 150mM NaCl, 5mM EDTA, 0.5% (v/v) NP40, 0.05% sodium deoxycholate, 1mM PMSF and protease inhibitor cocktail (Complete; Roche). For virus production, cells were split every 10 days. Supernatants were collected and stored at -80°C.

Density gradients. PLC3/HEV-p6 supernatant was concentrated with a Vivaspin ultrafiltration spin column (Sartorius). Concentrated supernatant or patient serum (500μl) was layered on a 7.5-40% iodixanol gradient, which was centrifuged at 160,000g for 16h at 4°C. Twelve fractions of 1ml were collected and their density was measured by refractometry. The HEV RNA titer was determined by RT-qPCR. Each fraction was used to infect A549 cells. Infectivity was determined by indirect immunofluorescence, immunoblotting, and RNA and viral titration. For patient samples, fractions were used for ORF2 probing, GNA pull-down, and RNA quantification.

Purification of infectious particles on iodixanol cushion. Supernatant of PLC3/HEV-p6 was concentrated by centrifugation through a 20% iodixanol cushion at 160,000g for 4h at 4°C. The cushion was resuspended in PBS, ultracentrifuged a second time, and the pellet was resuspended in PBS.

1 **Infection of humanized mice.** Primary human hepatocytes were transplanted into homozygous
2 uPA^{+/+}-SCID mice, as previously described ⁸. Humanized mice were inoculated via intrasplenic route
3 with HEV-p6 purified on iodixanol gradient (fraction6, F6p6, 8.7x10⁷ IU/mouse) or with the same
4 volume of fraction6 from a control gradient prepared with concentrated supernatant of non-transfected
5 PLC3 cells (F6 control). Non-transplanted mice inoculated with these preparations served as negative
6 controls. A chimeric mouse inoculated with a gt1 (Sar55, 2.8x10⁵ IU/mouse) stool suspension was
7 used as a positive control ⁹. Stool and plasma samples were collected on a weekly basis. Viral RNA
8 was detected and quantified in mouse plasma and stool using RT-qPCR, as described ⁹. Detection of
9 ORF1 and ORF2 in F6p6 mouse samples was performed as described in the supplementary material.
10 Sequencing of the S17 region was performed as described ⁹.
11

12 **Transmission electron microscopy (TEM).** The formvar-carbon TEM grids (S162, Oxford
13 Instruments) were either incubated with 0.01% poly-L-lysine for 30min at room temperature (RT) or
14 with poly-L-lysine and then with anti-ORF3 (Bioss antibodies), anti-ORF2 (1E6), or isotype-matched
15 antibodies (20µg/ml) for 1h at RT. Grids were washed in PBS and incubated for 2h at RT with viral
16 samples. TEM grids were washed in PBS and incubated for 20min in 4% paraformaldehyde and 1%
17 glutaraldehyde in 0.1M phosphate buffer, pH7.2. Particles trapped on grids were stained with 0.5%
18 uranyl acetate before examination under a JEOL-1230 TEM. For delipidation, particles were either
19 treated for 1h at 37°C with 1% sodium deoxycholic acid, 0.1% trypsin, then processed for TEM, or
20 treated in the same conditions then layered on an iodixanol gradient. After determining density and
21 RNA levels, fraction 11 was processed for TEM.
22

23 **Glycosidase digestions.** Protein samples were denaturated for 10min at 95°C in glycoprotein
24 denaturing buffer (New England Biolabs). Digestions with glycosidases were carried out for 4h at
25 37°C in the presence of 1% NP40 and the buffer provided by the manufacturer (NEB). Samples
26 prepared in the same conditions but without glycosidase were used as controls.
27

28 **GNA pull-down.** Agarose-conjugated GNA beads were incubated for 2h at RT with 50-500µl of
29 patient serum or 100µl of supernatant of PLC3/HEV-p6. Beads were washed 8 times with PBS 0.5%
30 NP40. Proteins were eluted in Laemmli Buffer and analyzed by SDS-PAGE. Unconjugated agarose
31 beads were used as a negative control.
32

33 **Patient samples.** Patient samples were collected in France between 2012 and 2016. This was a non-
34 interventional study. Samples were obtained only *via* standard viral diagnostics following a
35 physician's order (no supplemental or modified sampling). Data were analyzed anonymously. The
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 French Public Health Law (CSP Art L 1121-1.1) does not require written informed consent from
2 patients for such a protocol.

3
4

5 **Detection of HEV-Ag.** Gradient fractions were diluted in PBS and Ag levels were measured with the

6 Wantai HEV-Ag ELISA^{Plus} kit (Wantai Biological Pharmacy Enterprise) according to the

7 manufacturer's instructions.
8
9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

1 Results

2 3 4 Establishment of an efficient HEV cell culture system

5 In an attempt to establish a cell culture system for HEV, we first analyzed HEV replication in
6 two subclones of the PLC/PRF/5 cell line, namely PLC1 and PLC3 cells. We used the *Gaussia*
7 luciferase (GLuc)-expressing HEV gt3 replicon named HEV-p6GLuc⁶, in which the ORF2 coding
8 sequence was replaced with the secreted GLuc sequence. Thus, the amount of secreted GLuc is
9 proportional to viral RNA synthesis and consequently to HEV replication. PLC1, PLC3, and parental
10 PLC/PRF/5 cells were electroporated with HEV-p6GLuc RNA or with a non-replicative HEV-p6GLuc
11 genome (HEV-p6GLucGAD). The replication levels of HEV-p6GLuc steadily increased over time in
12 the three cell lines (**Figure 1A**), but PLC1 and PLC3 cells showed higher HEV replication fold
13 increase, as compared to PLC/PRF/5 cells. Experiments were thereafter conducted using PLC1 and
14 PLC3 cells.

15 We assessed the ability of PLC1 and PLC3 cells to express viral proteins and produce
16 infectious particles in kinetics experiments. PLC1 and PLC3 cells were electroporated with the HEV-
17 p6 RNA strain⁶. Immunofluorescence with anti-ORF2 and anti-ORF3 antibodies showed that over
18 80% of cells expressed viral proteins (**Figure 1B**), indicating that PLC1 and PLC3 cells are highly
19 transfectable, and that robust replication and expression of viral genome likely occur in these cells. It
20 must be noted that ORF2 expression was inhibited in the presence of Sofosbuvir (SFV) (**Figure S1**),
21 confirming the specificity of the signal.

22 We next analyzed the expression of ORF2 and ORF3 proteins in the cell lysates and
23 supernatants of HEV-p6 electroporated PLC1 and PLC3 cells by western blotting (WB) at different
24 time points. Importantly, the ORF2 protein was detected in the cell lysates and supernatant of PLC1
25 cells as early as 2 and 4 days post-electroporation (p.e.), respectively (**Figure 1C**). In HEV-p6
26 electroporated PLC3 cells, expression of the ORF2 protein was slightly delayed. It must be noted that
27 PLC3 cells grow more slowly than PLC1 cells, which could explain the observed differences. In
28 addition to the major product of ORF2, ORF2-related proteins with lower molecular weights were also
29 detected in cells and supernatants, indicating that the ORF2 capsid protein likely undergoes post-
30 translational modifications. The ORF3 protein was also early detected at 2 and 4 days p.e. in PLC1 and
31 PLC3 cell lysates, respectively (**Figure 1C**). In contrast, the ORF3 protein was faintly detected in the
32 supernatants of electroporated cells, indicating that this protein is mainly expressed intracellularly.

33 The major ORF2 product in the supernatant (**Figure 1D, Sup**) displayed a higher apparent
34 molecular weight than the intracellular form (**Figure 1D, Cells**), suggesting that the highly secreted
35 ORF2 protein likely undergoes post-translational modifications. Comparison of intracellular and
36 extracellular ORF3 proteins showed that the secreted ORF3 protein migrated slightly faster than the
37

intracellular protein (**Figure 1D**) likely reflecting differences in protein phosphorylation¹⁰ or undescribed modifications of the ORF3 protein.

Viral RNA and infectious particles were also monitored in the supernatants of transfected cells collected on different days p.e. HEV RNA levels were assessed by RT-qPCR. High RNA levels were detected as early as 2 days p.e. (**Supplementary Table 1**). RNA titers increased progressively and reached 1.1×10^8 and 3.3×10^7 copies/ml at day 10 for PLC1 and PLC3 cells, respectively (**Supplementary Table 1**). In parallel, infectious viral titers were determined and reached 7×10^3 and 1.5×10^3 ffu/ml for PLC1 and PLC3 cells, respectively. These results indicate that assembly of infectious viral particles occurs very early and equally in HEV-p6 electroporated PLC1 and PLC3 cells. However, HEV infectivity represents 1.5×10^4 RNA copies/ffu for PLC1 cells and 2.2×10^4 RNA copies/ffu for PLC3 cells, indicating that the assembly of infectious HEV particles is likely an inefficient process. However, we cannot exclude the possibility that a viral or cellular inhibitor blocks HEV infection and biases the infectious titers. Further experiments were carried out using PLC3 cells.

ORF2 capsid protein is massively produced but only a small fraction is assembled into infectious particles.

To produce large amounts of infectious supernatants, we cultured HEV-p6 transfected PLC3 cells during 47 days. Supernatants were pooled, concentrated, and fractionated on an iodixanol gradient. The distribution of ORF2 protein, ORF3 protein, RNA and infectious viral particles was analyzed from each fraction (**Figure 2**). ORF2 protein was detected from fractions 2 to 7 but more abundantly in fractions 3 to 5 (**Figure 2A**). As observed in the supernatants of transfected cells (**Figure 1C**), ORF2 protein in fractions 2 to 5 was detected as two products, one major product of approximately 90kDa (ORF2g) and a smaller product of around 75kDa (ORF2c). ORF2-related proteins with lower molecular weights were also detected at the top of the gradient in fractions 2 to 5, which might correspond to additional processed forms of the proteins. In contrast, the ORF2 protein was mainly detected as an 80kDa product (ORF2i) in fractions 6 and 7, which corresponds to the size of intracellular ORF2 (**Figure 1C**). The ORF3 protein was exclusively detected in fractions 5 to 7 but most abundantly in fraction 6 (**Figure 2A**). Interestingly, only one major peak of RNA was detected in fraction 6, with a density of 1.10 g/ml (**Figure 2B**). Therefore, a large amount of capsid protein (fractions 2 to 4) was not associated with the viral RNA while the ORF3 protein was.

The infectivity of each fraction was analyzed by infecting A549 cells. Expression of ORF2 and ORF3 proteins was analyzed by WB (**Figure 2C**) and indirect immunofluorescence (**Figure 2D** and data not shown) five days post-infection. ORF2i and ORF3 proteins were detected in the lysates of cells infected with fractions 5, 6 and 7 (**Figure 2C**), suggesting that infectious particles were associated with these fractions. Indeed, immunofluorescence staining of A549 cells inoculated with fractions 5, 6 and 7 were positive for ORF2 protein expression whereas cells inoculated with fractions

1 to 4 and fractions 8 to 12 were negative (**Figure 2D** and data not shown). Fraction 6 showed the highest infectious titer (5×10^6 ffu/ml). While ORF2g and ORF2c proteins were detected in cells inoculated with fractions 3 and 4 (**Figure 2C**), no specific infection was observed with these fractions by immunofluorescence (data not shown), indicating that ORF2g and ORF2c are likely very stable proteins binding to the cell surface that can be detected after several days of incubation.

It must be noted that the exosomal CD81 tetraspanin was detected in infectious fractions (**Figure 2A**), supporting the hypothesis that HEV particles likely exploit the exosomal secretory pathway for their egress ¹¹.

Together, our results indicate that during the HEV lifecycle, the ORF2 capsid protein is massively produced, but only a small fraction (ORF2i) is assembled into infectious particles that are secreted through the exosomal pathway.

Infection of human liver chimeric mice with HEVcc particles.

Recently, human liver chimeric mice have been described as valuable models for studying *in vivo* chronic HEV infection and evaluating antiviral molecules ^{9,12-14}. Establishment of HEV infection in chimeric mice was achieved after inoculation of gt1 or gt3 virions. However, inoculation of mice with non-treated cell culture supernatant-derived particles did not result in robust infection. Therefore, we next evaluated whether our HEVcc particles were able to infect primary human hepatocyte (PHH)-transplanted mice ⁹. Chimeric mice were inoculated via intrasplenic route with either fraction 6 of HEV-p6 (F6p6) purified on iodixanol gradient (Figure 2) or fraction 6 of a control gradient prepared from non-transfected PLC3 cells supernatant (F6 control, neg 1) (**Figure 3**). A human chimeric mouse inoculated with a gt1 stool suspension (Sar55) was used as a positive control ⁹. A non-transplanted mouse inoculated with F6p6 was used as a second negative control (neg 2). While to a lesser extent than the gt1-infected mouse, the F6p6-inoculated chimeric mouse still showed signs of active infection (**Figure 3**). Indeed, HEV RNA was detected in stools of F6p6-inoculated chimeric mouse from week 2 to 10 with a significant increase from week 8 to 10 (**Figure 3A** and **3B**). Genomic HEV RNA was also detected in mouse liver (**Figure 3C**) and small intestine content (**Figure 3D**). RNA load in the F6p6-inoculated mouse increased more slowly as compared to the gt1-inoculated mouse, as previously described ⁹ but for the first time, we demonstrate a robust infection of a chimeric mouse inoculated with HEV particles derived from cell culture supernatant.

Since HEV-p6 strain contains the human S17 ribosomal protein fragment that confers a growth advantage ^{6,15}, we next sequenced this region of HEV-p6 from the F6p6-infected mouse (stool week 9 p.i. and one liver piece) and compared it to the inoculum. We did not find any reversion of adaptive mutations in the S17 region (data not shown).

1 Ultrastructure of HEV particles.

2 Recently, a new strategy based on the direct specific immunocapture (IC) of hepatitis C virus
3 (HCV) particles on transmission electron microscopy (TEM) grids led, for the first time, to the precise
4 description of their ultrastructure ¹⁶. To define the morphology of HEVcc particles, which has never
5 been precisely described, we used the same approach on isolated infectious particles. We first analyzed
6 material captured on grids coated with poly-L lysine, a polycationic attachment factor. We observed a
7 fairly homogeneous population of particles of 40-70nm in size (**Figure 4A**). We next performed IC
8 with an antibody specific to the ORF3 protein that had been described as exposed on lipid-associated
9 HEV particles. We observed particles with an apparent internal icosahedral substructure likely
10 corresponding to the capsid (**Figure 4A**). The calculation of size distribution showed that particle sizes
11 ranged from 40nm to 70nm. In contrast, no particles were observed when an anti-ORF2 (1E6) (**Figure**
12 **4A**) or isotype control antibodies (data not shown) were used. However, when viral preparation was
13 first partially delipidated by sodium deoxycholate and trypsin (DT) treatment before IC with the anti-
14 ORF2 antibody, two populations of particles were immunocaptured: a major population consisting of
15 particles of 30-50nm in size and a more heterogeneous population with particles of 90-140nm (**Figure**
16 **4B**). Thus, DT treatment unmasked the 1E6 epitope on viral particles and led to IC of small HEV
17 particles that likely correspond to naked virions. However, DT treatment did not fully remove ORF3
18 and associated lipids since some particles were still captured by an anti-ORF3 antibody (**Figure 4B**).
19 The larger size of these particles is likely due to dissociation of their lipid coats. In contrast, when DT-
20 treated particles were purified on density gradient before IC (**Figure 4C**, Fraction F11), a highly
21 homogeneous population of particles of approximately 32nm was immunocaptured with 1E6 while no
22 particles were captured by IC anti-ORF3. These particles, with a density of 1.18g/ml, displayed an
23 icosahedral structure likely corresponding to naked capsids.

24 We next analyzed the ultrastructure of authentic particles from three HEV-infected patient sera
25 (HEVser). As for HEVcc, no particles were observed by IC anti-ORF2 or IC with irrelevant antibodies
26 (data not shown). In contrast, IC anti-ORF3 resulted in the efficient isolation of pleomorphic
27 populations. HEVser1 and HEVserST-1 particles had a similar morphology to HEVcc particles while
28 HEVser2 particles displayed a thick outer layer likely corresponding to lipids (**Figure 5A**). The
29 calculation of size distribution of immunocaptured particles showed that the mean and median
30 diameters of HEVser particles were generally larger than those of HEVcc particles and differed
31 between patients (**Figure 5B**). Particles from HEVser2 were the largest with a mean diameter of
32 120nm. **These results suggest that additional components, which could be the lipid content of particles,**
33 **likely determine particle size, as described for HCV particles ¹⁶. However, further investigations will**
34 **be needed to further characterize HEV particles from patients.**

35 **Lastly, we analyzed the ultrastructure of stool particles from the ST-1 HEV-infected patient. In**
36 **contrast to HEVcc and HEVser, stool particles were captured by IC anti-ORF2, whereas no particles**
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 were captured by IC anti-ORF3 (**Figure 5C**). Although particles appeared to be entangled in
 2 impurities limiting calculation of size distribution, the mean diameter of HEV stool particles was
 3 28nm, which is in accordance with previous observations ¹⁷. As for delipidated HEVcc, stool particles
 4 displayed an icosahedral structure likely corresponding to naked capsids. **No particles were captured**
 5 **from non-infected patient stools.**

6 **Characterization of the different forms of ORF2 protein.**

7
 8
 9 We developed a purification system using a 20% iodixanol cushion to easily separate infectious
 10 particles (ORF2i, **Figure 6A, Pellet**) from ORF2g/ORF2c proteins that are not associated with
 11 infectious particles (**Figure 6A, Top**).

12
 13 HEV produces large amounts of secreted ORF2g/ORF2c proteins that are likely
 14 glycosylated/processed forms of the ORF2 protein. In contrast, infectious particle-associated ORF2
 15 protein (ORF2i) purified by iodixanol gradient (F6p6) or cushion (Pellet/Cushion) displayed the same
 16 size as intracellular ORF2 protein (Cells) (**Figure 6B**), indicating that ORF2i likely does not undergo
 17 post-translational modifications.

18
 19 Since the ORF2 protein sequence contains three potential sites for N-linked glycosylation and
 20 multiple sites for O-linked glycosylation, we next analyzed the sensitivity of ORF2 proteins to
 21 treatment with different glycosidases (**Figure 6C**). Endoglycosidase H (EndoH) cleaves within the
 22 chitobiose core of high mannose and some hybrid oligosaccharides from N-glycoproteins. Peptide-N-
 23 Glycosidase F (PNGaseF) cleaves between the innermost N-acetyl glucosamine and asparagine
 24 residues of high mannose, hybrid and complex oligosaccharides from N-glycoproteins. O-Glycosidase
 25 (O-Gly) catalyzes the removal of some O-linked disaccharides. Neuraminidase (Neura) catalyzes the
 26 hydrolysis of sialic acid residues from N- and O-glycoproteins. It should be noted that terminal sialic
 27 acids block the action of O-Gly. The ORF2i protein expressed from cell lysates or purified HEV
 28 particles was resistant to glycosidase digestions (**Figure 6C**), indicating that this protein is not N- or
 29 O-glycosylated. In contrast, secreted ORF2g/ORF2c proteins were sensitive to digestion with EndoH
 30 and PNGaseF glycosidases, as attested by the mobility shift upon treatment, indicating that these
 31 proteins are N-glycoproteins. ORF2g/ORF2c proteins were resistant to O-Gly treatment but sensitive
 32 to treatment with Neura and more markedly to a combination of Neura and O-Gly. These results
 33 indicate that ORF2g/ORF2c proteins are sialylated and O-glycosylated proteins. Importantly,
 34 ORF2g/ORF2c proteins were precipitated by a Galanthus Nivalis Agglutinin (GNA) pull-down, a
 35 lectin that interacts with high-mannose-type glycans confirming the oligomannosidic nature of
 36 ORF2g/ORF2c N-glycans (**Figure 6D**) and allowing the easy and specific precipitation of
 37 ORF2g/ORF2c proteins.

38
 39 We demonstrated that secreted ORF2g/ORF2c are glycosylated proteins, indicating that these
 40 proteins go through the secretory pathway. However, ORF2g/ORF2c proteins were not detected at the
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65

1 intracellular level. We therefore hypothesized that ORF2g/ORF2c proteins might move rapidly
 2 through the secretory pathway and be secreted quickly without intracellular accumulation. We thus
 3 treated HEV-p6 expressing PLC3 cells with Brefeldin A (BFA), a protein secretion inhibitor¹⁸
 4 (**Figure 6E**). Upon BFA treatment, secretion of ORF2g/ORF2c proteins was blocked. Interestingly, a
 5 diffuse band likely corresponding to ORF2g and a faint band likely corresponding to ORF2c were
 6 detected in the lysate of BFA-treated cells, indicating that upon protein secretion blocking,
 7 ORF2g/ORF2c proteins accumulate in the cell, thus validating our hypothesis.

8 We next analyzed the sequence of ORF2 proteins by mass spectrometry. Viral particles
 9 purified on iodixanol cushion and ORF2g/ORF2c proteins immunoprecipitated with an anti-ORF2
 10 antibody (4B2) were resolved by SDS-PAGE. The Colloidal blue stained bands corresponding to
 11 ORF2i, ORF2g and ORF2c in WB (**Figure S2**) were digested in-gel with trypsin or AspN and then
 12 analyzed by nanoLC-MS/MS. Identified peptides and sequence covering are shown in **Figure S2**. For
 13 the three proteins, the C-terminal end was fully covered, demonstrating the absence of processing at
 14 their C-termini. For ORF2i protein, a semi-tryptic peptide covering half of the signal peptide (SP) was
 15 unexpectedly identified (**Figure S2A**, dashed line), suggesting that the SP of ORF2i might not be
 16 cleaved. For ORF2g, tryptic and semi-AspN peptides starting with Ser³⁴ were identified, suggesting
 17 that the first aa of the ORF2g protein might correspond to Ser³⁴ (**Figure S2B**). For ORF2c, tryptic
 18 peptides starting with Iso²³⁴ were identified, suggesting that the first aa of the ORF2c protein might
 19 correspond to one of the aa in proximity to Iso²³⁴ (**Figure S2C**). Since semi-tryptic and semi-AspN
 20 peptides correspond to either natural protein processing or non-specific proteolytic events during
 21 proteomics analyses, we further performed labeling with N-succinimidylsuccinylmethyl tris
 22 (2,4,6-trimethoxyphenyl) phosphonium bromide (TMPP-Ac-OSu), which binds specifically to the N-
 23 terminus of intact proteins¹⁹. Peptides identified with TMPP-Ac-OSu modification confirmed that the
 24 first aa of ORF2i and ORF2g corresponds to Leu¹⁴ and Ser³⁴, respectively (**Figures 6F, S2 and S3**). In
 25 contrast, as TMPP-Ac-OSu labeling did not identify the first aa of ORF2c, further studies are
 26 necessary to clarify this observation. Together, these data indicate that the ORF2g protein loses its SP
 27 and is likely processed by secretory pathway proteases. In contrast, the ORF2i protein is not processed
 28 by a signal peptidase and therefore likely not translocated into the ER lumen.

30 ORF2g/ORF2c proteins are the major antigens in HEV-infected patient sera

31 Since we demonstrated that in cell culture, HEV mainly produces glycosylated forms of ORF2
 32 proteins that are not associated with infectious particles, we next sought to determine whether the same
 33 occurs in infected patients. Sera from ten chronically infected HEV patients and from five HEV-
 34 negative patients were precipitated by GNA pull-down and probed for the ORF2 protein (**Figure 7A**),
 35 as described above. GNA-pulldown of PLC3/HEV-p6 supernatant was used as a positive control.
 36 Strikingly, 8 and 5 out of 10 HEV-positive sera displayed large amounts of the ORF2g and ORF2c
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65

1 proteins, respectively. ORF2 proteins were not detected in HEV-negative sera. In addition, the
2 detection of ORF2g/ORF2c proteins was dependent neither on the patient's HEV strain nor on the
3 serum viral load (**Supplementary Table 2**). Importantly, fractionation of a patient serum (P6 patient)
4 on an iodixanol gradient followed by GNA pull-down of each fraction (**Figure 7B**) demonstrated that,
5 as in cell culture, very large amounts of ORF2g/ORF2c proteins were isolated in light fractions
6 (fractions 4 and 5) and pull-down by GNA. However, these fractions were not associated with
7 infectious material, since they were not associated with the viral genome (**Figure 7C**). It should be
8 noted that the ORF2 proteins present in fraction 4 were likely not precipitated by GNA beads due to
9 the presence of high amounts of human albumin. Our results indicate that ORF2g/ORF2c proteins are
10 likely the major antigens in HEV-infected patient sera. Therefore, we quantified ORF2 proteins in
11 each fraction of the gradient with the Wantai HEV-antigen ELISA^{Plus} assay (**Figure 7D**). Interestingly,
12 the highest amount of antigen was detected in fraction 4, containing the ORF2g/ORF2c proteins,
13 whereas lower amounts of antigens were detected in the other fractions and notably in fraction 7, the
14 infectious fraction. Together, our results indicate that in infected patients, HEV produces high amounts
15 of glycosylated antigen protein that are not associated with infectious particles and might lead to a bias
16 in diagnosis of active HEV infection.

1 Discussion

2 By combining the highly replicative and cell culture-adapted p6 strain ⁶ and highly
 3 transfectable subclones of PLC/PRF/5 cells, we developed a new cell culture system for which viral
 4 replication and protein expression were detected very early post-transfection. Time-course experiments
 5 showed that the ORF2 protein was early and massively secreted into the supernatant of transfected
 6 cells, as recently reported ^{20,21}. Interestingly, ORF2 and ORF3 proteins migrated differently when
 7 detected either in cell lysate or supernatant, indicating that these proteins likely undergo post-
 8 translational modifications during their secretion. Further experiments would be necessary to identify
 9 such modifications in the ORF3 protein. The ORF2 protein contains three potential sites for N-linked
 10 glycosylation and multiple sites for O-linked glycosylation. Using expression vectors, it has been
 11 previously shown that the ORF2 protein is glycosylated and expressed on the cell surface ²²⁻²⁴, but it is
 12 not clear whether the glycosylated ORF2 protein is the natural form of the virion. Recently, it has been
 13 suggested that the HEV virion capsid is likely glycosylated ²⁰, although Graff *et al.* showed the
 14 opposite ²⁵. Our study revealed that HEV produces large amounts of ORF2 proteins, named ORF2g
 15 and ORF2c, that are secreted, sialylated, N- and O-glycosylated but are not associated with infectious
 16 virions. A large portion of ORF2 proteins is likely translocated into the ER lumen where they are N-
 17 glycosylated and likely processed by proteases to generate ORF2g and ORF2c proteins. These two
 18 proteins move rapidly through the secretory pathway where they are O-glycosylated and sialylated,
 19 then quickly secreted. Interestingly, the presence of RGRR residues upstream of the ORF2g N-
 20 terminus suggests that a furin-like protease might be involved in its maturation. Further experiments
 21 would be necessary to characterize glycosylation and processing sites in the ORF2 sequence, notably
 22 the mechanism leading to the production of the ORF2c protein. In contrast, the ORF2i protein seen on
 23 an intracellular level and in virions is likely not translocated into the ER lumen and stays in the
 24 cytosolic compartment. Our results suggest the existence of two production pathways for the HEV
 25 capsid protein: (i) a major non-productive pathway in which ORF2 proteins are delivered to the
 26 secretion route where they are processed and quickly secreted. (ii) a productive pathway in which
 27 cytosolic ORF2 proteins are delivered to the virion assembly sites. Further studies are needed to
 28 thoroughly investigate these pathways.

29 In contrast to previous studies ^{9,13}, we succeeded in infecting chimeric mice with gt3 HEVcc
 30 particles. The separation of infectious particles from ORF2g/ORF2c proteins by density gradient might
 31 explain our success, as these proteins interfere with the capacity of virions to infect target cells (**Figure**
 32 **S4**), using a mechanism which needs to be elucidated.

33 We found that during its lifecycle, HEV highly secretes glycosylated forms of the ORF2
 34 protein, which circulate in infected patients and are the major antigens in patient sera. It would be
 35 interesting to define which form of ORF2 protein is recognized by antibodies from patients that have
 36 resolved their infections. HEV may produce ORF2g/ORF2c proteins as immunological bait.

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Interestingly, using TEM analyses, we found that ORF2g/ORF2c proteins do not form particulate
2 material (data not shown) in contrast to other viruses such as hepatitis B virus, where the surface
3 antigen forms subviral particles.

4 Our TEM analyses showed that HEVcc are particles of 40-70nm in size displaying internal
5 structures and the ORF3 protein at their surface. DT treatment and ultracentrifugation uncloaked small
6 icosahedral capsids similar to those found in patient stools (¹⁷ and our study), indicating that HEVcc
7 are associated with lipids in which ORF3 is embedded. Our analyses showed that, although much
8 larger, HEVser particles have a morphology similar to HEVcc particles. HEVser virions display the
9 ORF3 protein at their surface and are likely highly associated with lipids. As HEVser diameters
10 differed between patients, it would be interesting to determine if the observed size variations are
11 related to lipid content, as recently demonstrated for HCV particles ¹⁶.

12 Recently, the Wantai HEV-Ag-ELISA assay was marketed for diagnosing HEV infection.
13 Comparative studies of this assay showed high levels of specificity and sensitivity ²⁶⁻²⁹. However,
14 some discrepancies between antigen detection and RNA quantification were found in some samples in
15 which the HEV antigen was detected in the absence of detectable RNA ²⁷⁻²⁹. In our hands, the antigen
16 assay was also very sensitive. However, we found that ORF2g/ORF2c proteins, which are not
17 associated with infectious virions, were the main antigens recognized by the kit. Together, these data
18 indicate that the results obtained with the HEV-Ag-ELISA assay must be cautiously interpreted.
19 Indeed, this assay might not necessarily detect an active infection, since ORF2g/ORF2c proteins seem
20 to be very stable in cell culture but likely also in patient sera ²⁸, suggesting that these proteins might
21 remain in patient sera even when HEV is no longer replicating in the liver.

1 **Figure legends**

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

Figure 1: HEV replication and protein expression in transfected PLC/PRF/5-derived cells. (A) PLC/PRF/5, PLC1 and PLC3 cells were electroporated with the HEV-p6Gluc replicon. For each time point, values are presented as fold increase compared to luciferase activities measured at 24h post-electroporation (p.e.). Activities were normalized to intracellular activities. Data are representative of three independent experiments. (B) PLC1 and PLC3 cells were transfected with the infectious HEV-p6 RNA. Five days p.e., ORF2 (red) and ORF3 (green) protein expression was analyzed by immunofluorescence. Nuclei are shown in blue. (C) ORF2 and ORF3 protein expression in cell extracts and supernatants at different time points p.e. (D) ORF2 and ORF3 protein expression in cell extracts and supernatants harvested at 10 days p.e..

Figure 2: Density gradient of HEV-p6 transfected PLC3 cell supernatant. Concentrated PLC3/HEV-p6 cell supernatant was layered on an iodixanol gradient and ultracentrifuged. Twelve fractions were collected and their densities were measured. (A) Expression of ORF2, ORF3 and CD81 proteins analyzed by WB. (B) HEV RNA levels in each fraction measured by RT-qPCR. A549 cells were infected with an aliquot of each fraction. Five days post-infection, protein expression was analyzed by WB in infected cell lysates (C) and by immunofluorescence (D). For clarity, only some infections are shown.

Figure 3: Infection of humanized mice with HEVcc. PHH-transplanted mice were inoculated by intrasplenic route with either fraction 6 of HEV-p6 purified on iodixanol gradient (F6p6) or fraction 6 of a control gradient prepared from the supernatant of non-transfected PLC3 cells (F6 control, neg1). A human chimeric mouse inoculated with a gt1 (Sar55) stool suspension was used as a positive control. A non-transplanted mouse inoculated with F6p6 was used as a second negative control (neg2). (A) The levels of plus strand-HEV RNAs (IU/ml) were quantified by RT-qPCR in mouse stools and plasma at different time points after inoculation. Standard deviations (SD) were omitted for clarity. LOQ, limit of quantification. Detection of RNAs by using ORF1 primers in mice stools (B) and liver (C). Stool CTL p6 was from a chimeric mouse inoculated with a p6 cell lysate⁹. (D) Detection of RNAs by using ORF2 primers. CTL, control; NTC, non-template control; wk, week; neg, negative; P1, piece 1; SI, small intestine.

Figure 4: Ultrastructure of HEVcc. Representative electron micrographs of particles immobilized on poly-L-lysine or immunocaptured (IC) with anti-ORF3 or anti-ORF2 antibodies. Histograms on the right show the immunocaptured particle size distribution for the indicated antibody. Mean, median and SD of particles diameter are indicated in the boxes. Grids were prepared with HEVcc (A) or with

1 HEVcc treated with 1% sodium deoxycholic acid and 0.1% trypsin (DT) (**B**). In (**C**), DT-treated
 2 particles were purified on density gradient. The infectious fraction containing the highest level of HEV
 3 RNAs (F11) and with a density of 1.18g/ml, was used for IC. Particles were stained with uranyl
 4 acetate dihydrate and observed using a JEOL-1230 electron microscope. Scale bars are indicated.

5
 6
 7 **Figure 5: Ultrastructure of HEV particles from patient sera and stool.** (**A**) Representative electron
 8 micrographs of IC anti-ORF3 with particles from three HEV-infected patient sera (HEVser). (**B**)
 9 Histograms show the immunocaptured particle size distribution. Mean, median and standard deviation
 10 (SD) of particle diameters are indicated in the boxes. (**C**) Representative electron micrographs of IC
 11 anti-ORF3 and IC anti-ORF2 of particles from HEV-infected patient stools (HEVstool) and non-
 12 infected patient stools (Stool neg). Scale bars and particle sizes are indicated.

13
 14
 15
 16
 17
 18
 19 **Figure 6: Characterization of the different ORF2 products.** (**A**) Detection by WB of ORF2
 20 proteins in the top and pellet of the PLC3/HEV-p6 cell supernatant purified onto iodixanol cushion.
 21 (**B**) Comparison of ORF2 products expressed in the cell lysates and supernatant of PLC3/HEV-p6
 22 cells, in infectious fraction 6 (F6p6) and non-infectious fraction 3 (F3p6) from iodixanol gradient, and
 23 in the pellet of PLC3/HEV-p6 cell supernatant purified on the iodixanol cushion. (**C**) PLC3/HEV-p6
 24 cell lysate, supernatant and purified HEV particles were denatured and digested with indicated
 25 glycosidases (+) or not (-). The dashed line shows the migration shift of ORF2 proteins following
 26 glycosidase treatment. (**D**) ORF2 protein detection after incubation of the supernatant of PLC3/HEV-
 27 p6 or PLC3 cells with GNA- or ProteinA-conjugated agarose beads. (**E**) PLC3/HEV-p6 cells were
 28 treated (+) or not (-) with Brefeldin A (BFA, 16h, 1µg/ml) and the ORF2 protein expression in cells
 29 and supernatant was analyzed. (**F**) Sequence of ORF2 proteins analyzed by nanoLC-MS/MS. The
 30 dashed line corresponds to the signal peptide. Frames indicate potential N-glycosylation sites. The first
 31 aa of ORF2i and ORF2g identified by TMPP-Ac-OSu labeling are in bold.

32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45 **Figure 7: ORF2g and ORF2c proteins are the major HEV antigens in infected patients.** (**A**) GNA
 46 pull-down on patient sera followed by ORF2 probing. Pull-down of PLC3/HEV-p6 supernatant was
 47 used as a positive control. (**B**) Fractionation on iodixanol gradient (7.5-40%) of the P6 patient serum
 48 and analysis of the ORF2 content of each fraction by WB and GNA pull-down. (**C**) HEV RNA levels
 49 in each fraction measured by RT-qPCR. (**D**) Detection of HEV Ag in each gradient fraction using the
 50 Wantai HEV-Ag ELISA^{Plus} kit. Results are expressed as signal to cut-off ratios (S/CO).

51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65

1 **References**

- 2
- 3 1. Debing Y, Moradpour D, Neyts J, et al. Update on hepatitis E virology: Implications for clinical
4 practice. *Journal of Hepatology* 2016;65:200–212.
- 5 2. Pischke S, Hartl J, Pas SD, et al. Hepatitis E virus: Infection beyond the liver? *Journal of*
6 *Hepatology* 2017;66:1082–1095.
- 7 3. Khuroo MS, Khuroo MS. Hepatitis E: an emerging global disease - from discovery towards
8 control and cure. *Journal of Viral Hepatitis* 2016;23:68–79.
- 9
- 10 4. Feng Z, Hensley L, McKnight KL, et al. A pathogenic picornavirus acquires an envelope by
11 hijacking cellular membranes. *Nature* 2013;496:367–371.
- 12 5. Okamoto H. Culture systems for hepatitis E virus. *J Gastroenterol* 2012;48:147–158.
- 13
- 14 6. **Shukla P, Nguyen HT**, Faulk K, et al. Adaptation of a genotype 3 hepatitis E virus to efficient
15 growth in cell culture depends on an inserted human gene segment acquired by recombination. *J*
16 *Virol* 2012;86:5697–5707.
- 17 7. Emerson SU, Nguyen H, Graff J, et al. In vitro replication of hepatitis E virus (HEV) genomes
18 and of an HEV replicon expressing green fluorescent protein. *J Virol* 2004;78:4838–4846.
- 19 8. Meuleman P, Libbrecht L, De Vos R, et al. Morphological and biochemical characterization of
20 a human liver in a uPA-SCID mouse chimera. *Hepatology* 2005;41:847–856.
- 21 9. Sayed IM, Verhoye L, Cocquerel L, et al. Study of hepatitis E virus infection of genotype 1 and
22 3 in mice with humanised liver. *Gut* 2017;66:920–929.
- 23 10. Zafrullah M, Ozdener MH, Panda SK, et al. The ORF3 protein of hepatitis E virus is a
24 phosphoprotein that associates with the cytoskeleton. *J Virol* 1997;71:9045–9053.
- 25 11. Nagashima S, Jirintai S, Takahashi M, et al. Hepatitis E virus egress depends on the exosomal
26 pathway, with secretory exosomes derived from multivesicular bodies. *Journal of General*
27 *Virology* 2014;95:2166–2175.
- 28 12. **Allweiss L, Gass S**, Giersch K, et al. Human liver chimeric mice as a new model of chronic
29 hepatitis E virus infection and preclinical drug evaluation. *Journal of Hepatology*
30 2016;64:1033–1040.
- 31 13. van de Garde MDB, Pas SD, van der Net G, et al. Hepatitis E Virus (HEV) Genotype 3
32 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection. *J Virol*
33 2016;90:4394–4401.
- 34 14. Sayed IM, Foquet L, Verhoye L, et al. *Antiviral Research*. *Antiviral Research* 2017;141:150–
35 154.
- 36 15. **Shukla P, Nguyen HT**, Torian U, et al. Cross-species infections of cultured cells by hepatitis E
37 virus and discovery of an infectious virus-host recombinant. *Proc. Natl. Acad. Sci. U.S.A.*
38 2011;108:2438–2443.
- 39 16. Piver E, Boyer A, Gaillard J, et al. Ultrastructural organisation of HCV from the bloodstream of
40 infected patients revealed by electron microscopy after specific immunocapture. *Gut* 2016.
- 41 17. Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 hepatitis transmitted via the fecal-oral route. *Intervirology* 1983;20:23–31.


- 2 18. Klausner RD, Donaldson JG, Lippincott-Schwartz J, Brefeldin A: insights into the control of
3 membrane traffic and organelle structure. *J Cell Biol* 1992;116:1071–1080.
- 4 19. Gallien S, Perrodou E, Carapito C, et al. Ortho-proteogenomics: Multiple proteomes
5 investigation through orthology and a new MS-based protocol. *Genome Research* 2008;19:128–
6 135.
- 7 20. Qi Y, Zhang F, Zhang L, et al. Hepatitis E Virus Produced from Cell Culture Has a Lipid
8 Envelope. *PLoS ONE* 2015;10:e0132503.
- 9 21. Shiota T, Li TC, Yoshizaki S, et al. Establishment of hepatitis E virus infection-permissive and -
10 non-permissive human hepatoma PLC/PRF/5 subclones. *Microbiol. Immunol.* 2015;59:89–94.
- 11 22. Jameel S, Zafrullah M, Ozdener MH, et al. Expression in animal cells and characterization of
12 the hepatitis E virus structural proteins. *J Virol* 1996;70:207–216.
- 13 23. Torresi J, Meanger J, Lambert P, et al. High level expression of the capsid protein of hepatitis E
14 virus in diverse eukaryotic cells using the Semliki Forest virus replicon. *J. Virol. Methods*
15 1997;69:81–91.
- 16 24. Zafrullah M, Ozdener MH, Kumar R, et al. Mutational analysis of glycosylation, membrane
17 translocation, and cell surface expression of the hepatitis E virus ORF2 protein. *J Virol*
18 1999;73:4074–4082.
- 19 25. Graff J, Zhou Y-H, Torian U, et al. Mutations within potential glycosylation sites in the capsid
20 protein of hepatitis E virus prevent the formation of infectious virus particles. *J Virol*
21 2008;82:1185–1194.
- 22 26. Trémeaux P, Lhomme S, Chapuy-Regaud S, et al. Performance of an antigen assay for
23 diagnosing acute hepatitis E virus genotype 3 infection. *J. Clin. Virol.* 2016;79:1–5.
- 24 27. Zhao C, Geng Y, Harrison TJ, et al. Evaluation of an antigen-capture EIA for the diagnosis of
25 hepatitis E virus infection. *Journal of Viral Hepatitis* 2015;22:957–963.
- 26 28. Behrendt P, Bremer B, Todt D, et al. Hepatitis E Virus (HEV) ORF2 Antigen Levels
27 Differentiate Between Acute and Chronic HEV Infection. *Journal of Infectious Diseases*
28 2016;214:361–368.
- 29 29. Geng Y, Zhao C, Huang W, et al. Detection and assessment of infectivity of hepatitis E virus in
30 urine. *Journal of Hepatology* 2016;64:37–43.


31
32
33 Author names in bold designate shared co-first authorship.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 ACKNOWLEDGEMENTS


2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

We thank Sandrine Belouzard, Karin Seron and Sophana Ung for their technical contribution. We thank Suzanne U. Emerson (NIH, USA) and Shoshana Levy (Stanford University, USA) for providing us with reagents. We thank Lydia Linna for proofreading the manuscript.







A




B





C





D











SUPPLEMENTARY MATERIAL

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein

Claire Montpellier^{a,#}, Czeslaw Wychowski^{a,#}, Ibrahim M. Sayed^{b,c}, Jean-Christophe Meunier^d, Jean-Michel Saliou^a, Maliki Ankavay^a, Anne Bull^d, André Pillez^a, Florence Abravanel^e, François Helle^f, Etienne Brochot^f, Hervé Drobecq^g, Rayan Farhat^a, Cécile-Marie Aliouat-Denis^a, Juliano G. Haddad^a, Jacques Izopet^e, Philip Meuleman^b, Anne Goffard^a, Jean Dubuisson^a, Laurence Cocquerel^a

^a University of Lille, CNRS, INSERM, CHU Lille, Pasteur Institute of Lille, U1019-UMR8204-CIIL- Center for Infection and Immunity of Lille, F-59000 Lille, France

^b Laboratory of Liver Infectious Diseases, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.

^c Microbiology and Immunology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.

^d Inserm-U966, University F. Rabelais, F-37032 Tours, France.

^e CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France.

^f EA4294, Laboratoire de Virologie, Centre Universitaire de Recherche en Santé, Centre Hospitalier Universitaire et Université de Picardie Jules Verne, Amiens, France

^g Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161-M3T-Mechanisms of Tumorigenesis and Target Therapies, Lille, France.

1 SUPPLEMENTARY MATERIALS AND METHODS

2
3 **Antibodies.** Two rabbit anti-ORF3 polyclonal antibodies were used in this study, one
4 provided by S.U Emerson (NIH, USA) ¹ and the other from Bioss Antibodies. Mouse anti-
5 HEV ORF2 monoclonal antibodies (MAbs) (1E6, antibody registry #AB-827236 and 4B2
6 #AB-571018) were from Millipore. Anti-CD81 MAb (5A6) was kindly provided by S. Levy.
7 Secondary antibodies were from Jackson ImmunoResearch.

8
9 **Luciferase assay.** Cells were electroporated with HEV-p6GLuc RNA or HEV-p6GlucGAD
10 RNA. One day post-electroporation, the medium was collected (D1, Day 1) and replaced with
11 DMEM/M199/Additives. Every two days (D2, D4, D6, D8, D10) during 10 days, a sample of
12 medium was collected from each well. GLuc activities were determined with the *Renilla*
13 luciferase assay system (Promega) and using a Tristar LB941 luminometer (Berthold). Values
14 were normalized relative to those at D1.

15
16 **Infectious titers.** A549 cells were infected with dilutions (10^{-1} to 10^{-7}) of infectious
17 supernatants or fractions of iodixanol gradient for 6h at 37°C. The inocula were removed and
18 replaced by fresh complete medium. Five days post-infection, cells were fixed and processed
19 for indirect immunofluorescence. Cells labeled with anti-ORF2 antibody 1E6 were counted as
20 infected cells. The number of infected cells was determined for each dilution and used to
21 define the infectious titer in focus forming unit (ffu)/ml.

22
23 **Indirect immunofluorescence.** Cells were fixed with methanol/acetone (1v:1v) 20 min at -
24 20°C and then processed for immunofluorescence detection as previously described ². Mouse
25 anti-HEV ORF2 MAb (1E6/IgG2b) rabbit anti-ORF3 polyclonal antibody (S.U. Emerson)
26 were used at a 1/800 and 1/2000 dilution, respectively. Image acquisition was carried out
27 using an Axiophot 2 microscope (Zeiss).

28
29 **RNA extraction and quantification.** Samples were treated with RNase A during 30 min at
30 room temperature before nucleic acid extraction with the QIAamp Viral RNA Mini Kit
31 (Qiagen). HEV RNA levels were quantified by RT-qPCR (real-time-quantitative polymerase
32 chain reaction) assay by using primers and probes targeting a conserved 70 base pair region in
33 the ORF2/ORF3 overlap, as previously described ³.

34

1 **Detection of HEV ORF1 in mouse liver and stool samples.** RNA extracted from mouse
2 stool and mouse liver was converted into cDNA using Superscript IV enzyme (Life
3 Technologies, Belgium) with specific primers ⁴ according to the manufacturer's instructions.
4 10 µl of purified cDNA was used in first PCR run using ORF1 primers ⁴ and Dream Taq
5 DNA polymerase (Thermo Fischer Scientific, Belgium) according to the following
6 conditions: initial denaturation at 95°C for 2 minutes, followed by 40 cycles of amplification
7 (denaturation at 95°C for 30 sec, annealing at 55°C for 30 Sec, extension at 72°C for 1 min)
8 and final extension at 72°C for 5 min. 10 µl of the first PCR product was used for the second
9 PCR run using Dream Taq DNA polymerase according to the following conditions: initial
10 denaturation at 95°C for 2 minutes, followed by 20 cycles of amplification (denaturation at
11 95°C for 30 sec, annealing at 55°C for 30 Sec, extension at 72°C for 30 sec) and final
12 extension at 72°C for 5 min; the expected band size was 415 bp.

13

14 **Detection of HEV ORF2 in mouse samples.** First, a one step RT-PCR was performed on
15 10µl of extracted RNA using the LightCycler Multiplex RNA Virus Master (Roche, Belgium)
16 in combination with the primers RT_5'-CCCTTRTCYTGCTGMGCATTCTC-3', Fow_5'-
17 AATTATGCYCAGTAYCGRGTTG-3' and Rev_5'-CCCTTRTCYTGCTGMGCATTCTC-
18 3' according to the following conditions: RT step at 50°C for 10 min, initial denaturation at
19 95°C for 1 minute, followed by 40 cycles of amplification (denaturation at 95°C for 5 sec,
20 annealing at 47°C for 45 sec, and extension at 60°C for 45 sec) and final extension at 60°C
21 for 7 minutes. Nested PCR reaction was done on 10µl of the first-round PCR product using
22 Taq DNA polymerase (New England Biolabs, MA, USA) and the primers Fow_5'-
23 GTWATGCTYTGATWCATGGCT-3' and Rev_5'-AGCCGACGAAATCAATTCTGTC-
24 3' according to the following conditions: initial denaturation at 95°C for 30 sec, followed by
25 30 cycles of amplification (denaturation at 95°C for 30 sec, annealing at 47°C for 45 sec, and
26 extension at 68°C for 40 sec) and final extension at 68°C for 7 minutes. The expected size of
27 the nested PCR product was 348bp.

28

29 **Particle size distribution.** Series of electron micrographs (numbers as indicated) were
30 acquired at random from anti-ORF2 or anti-ORF3 IC TEM grids. The images were then
31 analyzed with Image-J software to determine the particle size distribution.

32

33 **Mass spectrometry and N-terminus identification.** For ORF2i analyses, viral particles
34 purified on iodixanol cushion were used. For ORF2g/ORF2c analyses, proteins from a

1 supernatant of PLC3/HEV-p6 cells were immunoprecipitated with the 4B2 anti-ORF2
2 antibody (Millipore). Proteins were resolved by SDS-PAGE. Colloidal blue stained bands
3 corresponding to ORF2i, ORF2g and ORF2c proteins in WB were cut into two slices for in-
4 gel digestion with trypsin or AspN. NanoLC-MSMS analyses of the protein digests were
5 performed on a UltiMate-3000 RSLCnano System coupled to a Q-Exactive instrument
6 (Thermo Fisher Scientific), as previously described ⁵. For N-terminus identification, viral
7 particles or immunoprecipitated ORF2g/ORF2c proteins were denatured for 20min at 80°C
8 then incubated for 3h at RT in 50mM NaPO₄, pH8.2, 10% CH₃CN, 1% SDS, 2mM TMPP-
9 Ac-OSu. Following trypsin digestion, mass spectrometry analyses were performed as above
10 and identified TMPP-labeled N-terminal peptides were validated as previously described ⁶.
11 Collected raw data were processed and converted into *.mgf peak list format with Proteome
12 Discoverer 1.4 (Thermo Fisher Scientific). MS/MS data were interpreted using search engine
13 Mascot (version 2.4.0, Matrix Science) with a tolerance on mass measurement of 0.2 Da for
14 precursor and 0.2 Da for fragment ions, against a composite target-decoy database (40584
15 total entries) built with Swissprot *Homo sapiens* database (TaxID=9606, 20 May 2016, 20209
16 entries) fused with the sequences of ORF2 (H9E9C9_HEV) and a list of classical
17 contaminants (119 entries). Carbamidomethylation of cysteine residues, oxidation of
18 methionine residues, protein N-terminal acetylation and propionamidation of cysteine
19 residues were searched as variable modifications. Up to one trypsin or three Asp-N missed
20 cleavages were allowed. Semi-specific cleavage was also authorized. Peptides were filtered
21 out according to the cutoff ion score > 25 and a minimal size of 7 amino acid residues.
22
23

1 **SUPPLEMENTARY TABLES**

2

3 **Supplementary table 1:** HEV RNA levels and infectious titers of PLC1/HEV-p6 and
 4 PLC3/HEV-p6 cell supernatants.

5

		Days post-electroporation					Fold increase
		2	4	6	8	10	
PLC1/HEV-p6	RNAs ^a	8x10 ⁶	2.4x10 ⁷	6x10 ⁷	7.7x10 ⁷	1.1x10 ⁸	14
	Titers ^b	2x10 ²	1x10 ³	2.5x10 ³	5x10 ³	7x10 ³	35
PLC3/HEV-p6	RNAs ^a	4.2x10 ⁶	5x10 ⁶	1.2x10 ⁷	2x10 ⁷	3.3x10 ⁷	8
	Titers ^b	<10	1.7x10 ²	5x10 ²	9x10 ²	1.5x10 ³	> 150

6 ^a HEV copies/ml

7 ^b ffu /ml

8

9

10

11

12 **Supplementary table 2 :** Features of HEV patient sera used in GNA pull-down

13

Patients	Genotype	Serum titer ^a	Amount used in GNA pull-down ^b	Ag levels ^c	ORF2 proteins ^d
P1	3c	1.3x10 ⁸	6.5x10 ⁶	17.4	ORF2g
P2	3c	3.7x10 ⁷	1.8x10 ⁶	19.4	ORF2g
P3	3c	2.1x10 ⁷	2.1x10 ⁶	17.4	ORF2g
P4	ND	2.0x10 ⁵	1.0x10 ⁵	20.2	ORF2g/ORF2c
P5	3f	7.0x10 ⁵	3.5x10 ⁵	ND	-
P6	3c	1.6x10 ⁸	1.6x10 ⁷	19.4	ORF2g/ORF2c
P7	3c	1.2x10 ⁷	1.2x10 ⁶	18.6	ORF2g/ORF2c
P8	3f	1.2x10 ⁵	0.6x10 ⁵	5	-
P9	3f	1.5x10 ⁵	0.7x10 ⁵	19.7	ORF2g/ORF2c
P10	3f	1.2x10 ⁶	0.6x10 ⁶	18.9	ORF2g/ORF2c

14 ^a in HEV RNA copies/ml

15 ^b in HEV RNA copies

16 ^c in S/CO values. Samples were diluted 100 times in PBS and quantified with the Wantai HEV-Ag-ELISA kit.

17 ^d detected in GNA pull-down + WB anti-ORF2

18

19

20

21

1 **SUPPLEMENTARY FIGURE LEGENDS**

2

3 **Supplementary figure 1: Sofosbuvir inhibits ORF2 expression.** HEV-p6 electroperated
4 PLC3 cells were cultured in the presence of Sofosbuvir (SFV) at the indicated concentrations.
5 At 10 days post-electroporation, ORF2 expression was analyzed by immunofluorescence (A)
6 and western-blotting (B) by using anti-ORF2 antibody 1E6. Tubulin was used as a loading
7 control.

8

9 **Supplementary figure 2: Characterization of the different ORF2 products.** Viral particles
10 purified on iodixanol cushion and ORF2g/ORF2c proteins immunoprecipitated with an anti-
11 ORF2 antibody (4B2) were resolved by SDS-PAGE. Colloidal blue (CB) staining and WB
12 are shown. The arrow indicates ORF2i (A), ORF2g (B) and ORF2c (C). The asterisk indicates
13 human albumin. H and L indicate the heavy and light chains of immunoglobulins used in IP.
14 ORF2 forms were digested in-gel with trypsin or AspN and analyzed by nanoLC-MS/MS.
15 Peptide covering is highlighted in grey on the sequence of each ORF2 product. Dashed lines
16 correspond to semi-trypsin and semi-AspN peptides. Leu¹⁴ and Ser³⁴ in bold correspond to the
17 first aa of ORF2i (A) and ORF2g (B), respectively, that were identified by semi-specific
18 cleavage and TMPP-Ac-Osu labeling. No evidence was found for the N-terminal part of
19 ORF2c (C).

20

21 **Supplementary figure 3: MS/MS spectrum of N-terminal peptides of ORF2i and ORF2g**
22 **proteins.** (A-B) Semi-trypsinic peptide 14-28 obtained from non-treated (A) or TMPP-Ac-Osu-
23 labeled (B) ORF2i protein. +572 corresponds to the TMPP mass increment following TMPP-
24 Ac-Osu labeling. (C-D) Trypsinic peptide 34-55 obtained from non-treated (C) or TMPP-Ac-
25 Osu-labeled (D) ORF2g protein. (E-F) Semi-AspN peptide 34-56 obtained from non-treated
26 (E) or TMPP-Ac-Osu-labeled (F) ORF2g protein.

27

28 **Supplementary figure 4 : ORF2g/c proteins inhibit HEVcc infection.** Huh-7.5 cells were
29 inoculated with purified HEVcc (HEV-p6) in combination with either fraction 3 (F3) of
30 iodixanol gradients prepared with a SN of PLC3/HEV-p6 cells (F3/ORF2g/c) or with F3 of
31 iodixanol gradients prepared with a SN of non-transfected PLC3 cells (F3/CTL). Huh-7.5
32 cells inoculated with an iodixanol cushion prepared with a SN of non-transfected PLC3 cells
33 are shown as Mock in the presence of F3/CTL or F3/ORF2g/c. Ten hours post-infection,
34 inocula were removed and replaced by fresh complete medium. Four days post-infection, cells

1 were fixed and processed for indirect immunofluorescence. Cells labeled with the anti-ORF2
2 antibody 1E6 were counted as infected cells. Values were adjusted to 100% infection for cells
3 infected with HEV-p6 + F3/CTL. Results are representative of three independent
4 experiments, but presented results are the mean +/- SD of two independent experiments
5 performed in duplicate. *** means a p value below 0.001.
6

1 **SUPPLEMENTARY REFERENCES**

2

3 1. Graff J, Nguyen H, Yu C, et al. The Open Reading Frame 3 Gene of Hepatitis E Virus
4 Contains a cis-Reactive Element and Encodes a Protein Required for Infection of
5 Macaques. *J Virol* 2005;79:6680–6689.

6 2. **Rocha-Perugini V, Montpellier C**, Delgrange D, et al. The CD81 partner EW1-2wint
7 inhibits hepatitis C virus entry. *PLoS ONE* 2008;3:e1866.



8 3. Abravanel F, Sandres-Saune K, Lhomme S, et al. Genotype 3 diversity and
9 quantification of hepatitis E virus RNA. *J. Clin. Microbiol.* 2012;50:897–902.


10 4. Sayed IM, Verhoye L, Cocquerel L, et al. Study of hepatitis E virus infection of
11 genotype 1 and 3 in mice with humanised liver. *Gut* 2017;66:920–929.






12 5. **Barthe P, Veyron-Churlet R**, de Visch A, et al. Mycobacterium tuberculosis LppM
13 Displays an Original Structure and Domain Composition Linked to a Dual Localization.
14 *Structure/Folding and Design* 2016;24:1788–1794.

15 6. Gallien S, Perrodou E, Carapito C, et al. Ortho-proteogenomics: Multiple proteomes
16 investigation through orthology and a new MS-based protocol. *Genome Research*
17 2008;19:128–135.

18

A**B**



A ORF2i**B** ORF2i**C** ORF2g**D** ORF2g**E** ORF2g**F** ORF2g